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Abstract
Cancer cells treated with the cyclooxygenase-2 inhibitor celecoxib show growth inhibition and
induced apoptosis. This study was conducted to determine if the same processes are relevant to
celecoxib’s effects on human colorectal adenocarcinomas treated in vivo. A cohort of 23 patients
with primary colorectal adenocarcinomas was randomized to receive a 7-day course of celecoxib
(400 mg b.i.d.) or no drug prior to surgical resection. Gene expression profiling was performed on
resected adenocarcinomas from the cohort of patients. Using fold change (>1.5) and p-value (<0.05)
cut-offs, 190 genes were differentially expressed between adenocarcinomas from patients receiving
celecoxib and those that did not. The celecoxib pre-treated samples showed decreased expression
levels in multiple genes involved in cellular lipid and glutathione metabolism; changes associated
with diminished cellular proliferation. Celecoxib pre-treatment for 7 days in vivo is associated with
alterations in colorectal adenocarcinoma gene expression which are suggestive of diminished cellular
proliferation.
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The inducible form of cyclooxygenase (COX), COX-2 is markedly up-regulated in
pathological conditions such as inflammation and cancer (1). For instance, a majority of
colorectal adenocarcinomas display increased expression levels of the COX-2 protein (2).
Additionally, COX-2 expression levels have been associated with invasion depth (3), liver
metastasis (4), and poor clinical outcome (5). Thus, the pharmacological inhibition of COX-2
activity has been explored as a therapeutic option for the management of colorectal cancer. In
fact, administration of celecoxib, a selective COX-2 inhibitor, for 6 months resulted in a 28%
reduction in the mean number of colorectal polyps in patients with familial adenomatous
polyposis (6). Furthermore, clinical trials of colorectal cancer patients are currently underway
investigating the addition of celecoxib to conventional chemotherapeutic regimens (7).
Investigations into celecoxib’s mechanism of action have shown that in vitro administration
leads to growth arrest and induction of apoptosis in a variety of cancer cells (8–12).
Interestingly, celecoxib’s anti-cancer effects appear to be independent of COX-2 inhibition,
involving the inhibition of cell cycle progression, induction of apoptosis and inhibition of
angiogenesis (Reviewed in (13)). Investigations into celecoxib’s mechanisms of action in
vivo have also been conducted. Gene expression analysis of healthy colon tissue from patients
with hereditary nonpolyposis colon cancer (HNPCC) receiving celecoxib for 12 months
displayed gene expression changes suggestive of alterations in immune response, cell adhesion
and transforming growth factor-β signaling (14).
However, the mechanism with which celecoxib exerts its chemotherapeutics effects in
colorectal tumors in vivo is currently not known. We conducted a Phase 0 study to examine
the effects of celecoxib pre-treatment on primary colorectal adenocarcinoma gene expression
to gain insight into the mechanisms underlying celecoxib’s effects in vivo. Our results indicate
that celecoxib pre-treatment in vivo is associated with multiple gene expression changes
consistent with alterations in cellular lipid metabolism, glutathione metabolism and cell
adhesion, in addition to differential expression of select genes involved in the immune
response, apoptosis and angiogenesis. These results suggest that celecoxib tips the balance
away from cellular proliferation towards growth inhibition in colorectal adenocarcinoma cells.
Materials and Methods
Patients undergoing surgical resection of histologically proven primary colorectal
adenocarcinomas were consented for participation in the study, which was approved by the
Washington University, School of Medicine Institutional Review Board (Table 1). The patients
enrolled in this study were randomized to receive either 400 mg celecoxib two times per day
or no COX-2 inhibitor for 7 days prior to surgical resection. This dose of celecoxib (400 mg
b.i.d.) was chosen because it elicited a significant decrease in the mean number of colorectal
polyps in patients with familial adenomatous polyposis (6). A 7 day treatment regimen allowed
the pharmacological evaluation to be performed without disrupting the surgical management
of the colorectal adenocarcinomas. Patients in both groups were not allowed to take aspirin or
other non-steroidal anti-inflammatory drugs (NSAIDS) before surgical resection to be eligible
to participate in this study. Patients had received no prior therapy for their cancer. There were
no apparent differences in either tumor cellularity or histology of the resection samples in the
two groups.
Total RNA was isolated from surgically resected, histologically confirmed colorectal primary
adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to
the manufacturer’s recommended protocol at the Siteman Cancer Center Tissue Procurement
Core (St. Louis, MO). Total RNA (5 ug) from each sample was converted to double stranded
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cDNA using a dT-T7 promoter primer. The double stranded cDNA was then used as a template
to synthesize biotinylated RNA, which was fragmented and hybridized to the Affymetrix
HG_U95av2 microarray chip (Santa Clara, CA) using Affymetrix’s labeling and hybridization
protocol within the Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO).
The array data was imported into GeneSpring GX 7.3 (Santa Clara, CA) and normalized using
GC-RMA. Genes with normalized expression standard deviations < 0.04 across all samples,
essentially unchanging genes, were excluded from further analysis. Unsupervised, hierarchical
clustering was performed on all samples and all changing genes (n = 10,083 genes) using
uncentered correlation as the similarity matrix with complete linkage clustering was performed
with Eisen’s clustering program (15). Using a volcano plot in GeneSpring, 190 genes were
identified with an absolute fold change greater than 1.5 and non-parametric p-value < 0.05
between adenocarcinomas from patients receiving celecoxib pre-treatment and
adenocarcinomas from patients receiving no drug. Hierarchical clustering (15) was performed
on all samples using the 190 differentially expressed genes identified in the volcano plot, using
uncentered correlation as the similarity matrix with complete linkage clustering. The resulting
heatmap and dendrogram were visualized using Java TreeView (16). Gene expression
enrichment analysis was performed using the analytical tools available at the DAVID website:
http://david.abcc.ncifcrf.gov/ (17). The data discussed in this publication have been deposited
in NCBIs Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are
accessible through GEO Series accession number GSE11237.
Results
Unsupervised hierarchical clustering using all genes with differing levels of expression across
all samples (n = 10,083 genes) showed no obvious separations based on: gender, tumor site,
clinical stage or celecoxib pre-treatment status (Figure 1). Differentially expressed genes
associated with celecoxib pre-treatment were identified by comparing gene expression
intensities in celecoxib-treated patients and patients receiving no drug using a volcano plot.
Using a > 1.5 absolute fold change and p<0.05 cut-offs, 35 genes displayed higher expression
values and 155 genes displayed lower expression values in adenocarcinomas from patients
receiving celecoxib relative to adenocarcinomas from patients receiving no drug (Figure 2A
and Supplemental Table 1). Hierarchical clustering of the adenocarcinoma samples across the
199 differentially expressed genes separated the samples into 3 main sub-clusters (Figure 2B).
In sub-cluster A, 8 of 9 tumor samples were from patients receiving no celecoxib pre-treatment.
In sub-cluster B, 6 of 7 tumor samples were from patients receiving celecoxib pre-treatment.
Sub-cluster C contains tumor samples from 4 patients receiving celecoxib and 3 patients
receiving no drug.
Gene annotation enrichment analysis was performed to examine which biological processes
were altered by celecoxib pre-treatment. Celecoxib pre-treatment for 7 days was associated
with the alteration of 23 genes involved in cellular lipid metabolism, 4 genes involved in
glutathione metabolism and 19 genes involved in cell adhesion (Table 2). In addition to these
significantly altered biological processes, tumor samples from patients receiving celecoxib pre-
treatment displayed changes in expression levels for genes associated with growth arrest
(growth arrest-specific 6, 1.7 fold change), apoptosis (BCL2-associated × protein, −1.9 fold
change), angiogenesis (angiogenin, −2.8 fold change; kallikrein-1, −2.6 fold change) and
inflammatory/immune response (interleukin-6, 4.4 fold change; S100 calcium binding protein
A8, 2.4 fold change).
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This first analysis of gene expression alterations associated with celecoxib pre-treatment in
patients with primary colorectal adenocarcinoma revealed changes of putative biological
relevance. Pre-treatment for only 7 days with pharmacological doses of celecoxib (400 mg
b.i.d.), resulted in alterations in numerous genes involved in cellular lipid metabolism,
glutathione metabolism and cell adhesion. In general, most of the genes involved in cellular
lipid metabolism (>90%) were down-regulated in patients receiving celecoxib pre-treatment
relative to patients receiving no drug. Importantly, several transcripts involved in fatty acid β-
oxidation (ACAA2, ECH1, HADHSC, HSD17B4; see Table 2 for gene names) were down-
regulated, suggesting that the tumors from patients receiving celecoxib pre-treatment have a
diminished capacity to generate energy. Since fatty acid metabolism has been shown to be
elevated in colorectal adenocarcinomas compared to normal colonic tissue (18), celecoxib may
exert its antiproliferative effects, at least in part, through counteracting the increase in fatty
acid metabolism associated with colorectal carcinogenesis.
Celecoxib pre-treatment was also associated with a decrease in the relative expression of
transcripts involved in glutathione metabolism, including 3 γ-glutamyltransferases (GGT1,
GGT2, GGTL4) and glutathione reductase. The decreased relative expression of these
transcripts suggests that tumors from patients receiving celecoxib pre-treatment have a reduced
capacity to handle oxidative stress. Additionally, increased expression of GGT1 has been
linked to the proliferative ability of colon cancer cells in vitro (19) by providing a growth
advantage over cells devoid of GGT1 expression (20). Furthermore, the proliferation of colon
cell lines is associated with increased activity of glutathione reductase, while decreased cell
proliferation is associated with decreased cellular glutathione content (21). The decreased
expression of glutathione metabolism related genes in this study therefore suggests a decrease
in cellular glutathione content by celecoxib pre-treatment and by extension, perhaps decreasing
the proliferative ability of the tumors.
In addition to altering expression of genes involved in lipid and glutathione metabolism,
celecoxib pre-treatment affected the expression level of genes involved in cell adhesion.
Several genes encoding for extracellular matrix proteins, including collagen, laminin, and von
Willebrand factor, showed increased relative expression in celecoxib pre-treated patients.
These results are in agreement with previous findings on the effects of celecoxib and other
NSAIDs on gene expression. For instance, colorectal cancer cells treated in vitro with aspirin
were also associated with the up-regulation of collagens (22). Alterations of genes involved in
cell adhesion were also noted in healthy colons from HNPCC patients treated with celecoxib
for 12 months (14). Another extracellular matrix protein, tenascin C, showed a relative increase
in expression levels following celecoxib pre-treatment. Tenascin C expression has been found
to be minimal in normal colonic mucosa, but elevated expression levels are observed in
colorectal adenocarcinomas (23).
Other gene expression alterations observed in patients receiving celecoxib pre-treatment
suggest a trend towards growth inhibitory influences in the tumors. For instance, the
inflammatory modulators, interleukin-6 and CXCL6 (chemokine (C-X-C motif) ligand -6),
displayed greater relative expression levels in tumor samples from patients receiving celecoxib
pre-treatment. Similar increases in inflammatory modulators, including interleukin-6, CXCL2
and CXCL3, have been noted in a breast epithelial cell line treated with 50 µM celecoxib for
48 hours, a treatment regimen associated with growth inhibition and induced apoptosis (9).
Angiogenin, a potent mediator of angiogenesis, has been found to promote proliferation of
gastric cancer cells (24) and has also been correlated with focal macrophage infiltration in
colorectal cancer (25). In this study, celecoxib pre-treatment was associated with decreased
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expression of angiogenin, again suggesting that celecoxib diminishes the proliferative ability
of colorectal cancer cells.
We must note that the cut-offs for differential expression between the two treatment groups
were of relatively low stringency. However, by using low stringency cut-offs for selecting
differentially expressed genes, we have achieved the goal of this pilot study by identifying
gene expression alterations associated with celecoxib pre-treatment, in vivo. It is promising
that even a short course of celecoxib resulted in gene expression changes in colorectal
adenocarcinomas. Previously, a 12 month regimen of celecoxib was found to induce expression
changes in over 1,000 genes in healthy colonic mucosa from HNPCC gene carriers (14). Many
of the expression changes were found in genes involved in immune response, cell adhesion,
transforming growth factor-β signaling, cell proliferation and angiogenesis. Similarly, the 7
day regimen of celecoxib employed in this study showed gene expression alterations in
colorectal tumor tissue, most notably changes in genes involved in cell proliferation, cell
adhesion and immune response. Interestingly, no genes involved in transforming growth factor-
β signaling were differentially expressed by the 7 day pre-treatment regimen of celecoxib,
possibly indicating that these effects of celecoxib occur after prolonged exposure.
How do the results from this study inform on the usefulness of celecoxib as an option for
colorectal cancer chemotherapy? This is an important issue, since the prolonged use of several
selective COX-2 inhibitors, including celecoxib, has been found to increase the risk of
cardiovascular side effects (26,27). However, the cardiovascular risks associated with long-
term use of celecoxib is rather ambiguous, as no increased cardiovascular risk was observed
in Prevention of Spontaneous Adenomatous Polyps (PreSAP) trial
(http://www.fda.gov/cder/drug/infopage/celebrex/celebrex-hcp.htm). Celecoxib appears to be
safer than other selective COX-2 inhibitors, but care should be taken when given to patients
already at risk for cardiovascular events (28). In regards to the therapeutic potential in colorectal
cancer, celecoxib given by itself at currently recommended doses (400 mg b.i.d.) appears to
lessen cellular proliferation of colorectal tumors, as evidenced by the results of this study.
However, the observed gene expression alterations appear to be relatively minor and it still
remains to be determined if a longer course of celecoxib treatment would significantly arrest
the growth of colorectal cancers. However, combination therapy of celecoxib with other
chemotherapeutics does not appear to be as promising. A recent Phase II study looking at the
effects of celecoxib treatment in metastatic colorectal cancer patients indicates that celecoxib
adds no added benefit to combined 5-fluorouracil/oxaliplatin chemotherapy (29). Additionally,
previous in vitro findings suggest that the combined use of celecoxib with 5-fluorouracil could
be counterproductive, as the growth arrest elicited by celecoxib interferes with 5-fluorouracil
mediated cytotoxicity (29,30). Further investigation is warranted to determine if celecoxib can
by employed as an adjunct to chemotherapeutic regimens that do not rely on enhanced cellular
proliferation for cytotoxicity.
In conclusion, our results suggest that celecoxib reduces the proliferative capacity of colorectal
adenocarcinomas. As with previous results, this small, short-term study, indicates that
celecoxib treatment is associated with gene expression alterations in the tumor itself that are
indicative of decreased cellular lipid and glutathione metabolism, along with an increased
immune response. These gene expression alterations, taken together, suggest that celecoxib
pre-treatment leads to growth inhibitory influences on colorectal tumors. This study suggests
possible gene expression alterations mediating the effects of celecoxib treatment on colorectal
adenocarcinoma cells in vivo. Additionally, these results should provide the impetus for larger
studies in the future, either using celecoxib treatment alone or in combination with other
chemotherapeutic regimens.
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Figure 1. Clustering of gene expression in colorectal adenocarcinoma patients
Unsupervised hierarchical clustering was performed on all samples using 10,083 genes with a
normalized expression standard deviations greater than 0.04. The dendrogram indicates that
the samples do not cluster based solely on any of the recorded phenotypic characteristics.
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Figure 2. Differentially expressed genes associated with celecoxib pre-treatment
2A: Volcano plot of gene expression changes between colorectal adenocarcinomas from
patients pre-treated and not pre-treated with celecoxib. 2B: Clustering using the 190
differentially expressed genes. Red indicates increased expression; green indicates decreased
expression and black indicates no difference.
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     Male 6 4
     Female 5 8
Tumor Site:
     Ascending Colon 3 2
     Cecum 3 4
     Descending Colon 1 0
     Hepatic Flexure 1 1
     Recto-Sigmoid Colon 0 2
     Sigmoid Colon 3 3
Clinical Stage:
     I 2 2
     II 3 6
     III 2 2
     IV 4 2
Pathological Grade:
     Poorly Differentiated 2 2
     Moderately Differentiated 7 9
     Well Differentiated 2 1
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Table 2
Differentially expressed genes in three overrepresented biological processes associated with celecoxib pre-treatment
Symbol Gene Name Fold Change
Cellular Lipid Metabolism: p<0.000002*
ACAA2 acetyl-Coenzyme A acyltransferase 2 −1.86
ACADSB acyl- Coenzyme A dehydrogenase, short/branched chain −1.63
AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase 2 −1.65
AKR1C1/AKR1C2 aldo-keto reductase family 1, member C 1.72
C14ORF1 chromosome 14 open reading frame 1 −1.58
CDS1 CDP-diacylglycerol synthase 1 −2.89
CYP2J2 cytochrome P450, family 2, subfamily J, polypeptide 2 −2.15
DGAT1 diacylglycerol O-acyltransferase homolog 1 (mouse) −2.04
DHCR24 24-dehydrocholesterol reductase −1.55
ECH1 enoyl Coenzyme A hydratase 1, peroxisomal −1.51
FABP1 fatty acid binding protein 1, liver −2.82
FDFT1 farnesyl-diphosphate farnesyltransferase 1 −1.58
HADHSC L-3-hydroxyacyl-Coenzyme A dehydrogenase, short chain −2.33
HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A reductase −1.81
HSD17B2 hydroxysteroid (17-beta) dehydrogenase 2 −2.11
HSD17B4 hydroxysteroid (17-beta) dehydrogenase 4 −1.66
PCCA propionyl Coenzyme A carboxylase, alpha polypeptide −2.60
PCCB propionyl Coenzyme A carboxylase, beta polypeptide −2.25
PIGF phosphatidylinositol glycan anchor biosynthesis, class F −1.60
RARRES2 retinoic acid receptor responder (tazarotene induced) 2 1.75
SLC27A2 solute carrier family 27 (fatty acid transporter), member 2 −2.54
UGT1A1 - A10 UDP glucuronosyltransferase 1 family −2.84
UGT8 UDP glycosyltransferase 8 −2.54
Glutathione Metabolism: p<0.001*
GGT1 gamma-glutamyltransferase 1 −1.54
GGT2 gamma-glutamyltransferase 2 −1.80
GGTL4 gamma-glutamyltransferase-like 4 −2.12
GSR glutathione reductase −1.67
Cell Adhesion: p<0.02*
CCL2 chemokine (C-C motif) ligand 2 2.62
CIB1 calcium and integrin binding 1 (calmyrin) −1.64
CLDN7 claudin 7 −1.71
COL16A1 collagen, type XVI, alpha 1 2.34
CTNNA1 catenin (cadherin-associated protein), alpha 1, 102kDa −1.68
FCGBP Fc fragment of IgG binding protein −7.09
GMDS GDP-mannose 4,6-dehydratase −2.07
ITGA6 integrin, alpha 6 −1.58
LAMA4 laminin, alpha 4 1.81
LGALS4 lectin, galactoside-binding, soluble, 4 (galectin 4) −2.57
LOXL2 lysyl oxidase-like 2 1.52
MAEA macrophage erythroblast attacher −1.51
MUC5AC mucin 5AC, oligomeric mucus/gel-forming −2.84
PECAM1 platelet/endothelial cell adhesion molecule (CD31 antigen) 2.21
TNC tenascin C (hexabrachion) 1.82
TNFAIP6 tumor necrosis factor, alpha-induced protein 6 1.93
TSPAN1 tetraspanin 1 −2.61
VCAM1 vascular cell adhesion molecule 1 1.69
VWF von Willebrand factor 1.80
NOTE: Fold change represents the difference in expression in celecoxib pre-treated patients versus patients receiving no drug pretreatment.
*
P-value represents the likelihood that the number of differentially expressed genes belonging to the biological process occurred by chance as determined
by the Fischer’s exact test.
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